{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Number of patients in remission at a median follow up of 15 months.","groups":[{"description":"INDUCTION THERAPY: Patients receive filgrastim SC daily beginning the day prior to chemotherapy and continuing until blood counts recover. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 5 days.\n\nCONSOLIDATION THERAPY: Patients receive filgrastim SC daily for 5 days beginning the day prior to chemotherapy. Patients receive clofarabine IV over 1 hour followed by cytarabine IV over 2 hours daily for 4 days.\n\nTreatment with induction therapy may continue for up to 2 courses and treatment with consolidation therapy may continue for up to 3 courses in the absence of disease progression or unacceptable toxicity.\n\nfilgrastim: Given SC\n\nclofarabine: Given IV\n\ncytarabine: Given IV","id":"OG000","title":"Treatment (Chemotherapy and Colony Stimulating Factor)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Event Free Survival","type":"PRIMARY","unitOfMeasure":"Participants"}